DDInter997 DDInter1435
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Ivacaftor {u} (Compound) binds {v} (Gene) CYP3A4
Ivacaftor {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Ivacaftor {u} (Compound) causes {v} (Side Effect) Pleuritic pain
Ivacaftor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Ivacaftor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etonogestrel
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Avapritinib
Ivacaftor {u} may lead to a major life threatening interaction when taken with {v} Fluconazole
Ivacaftor {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Ivacaftor (Compound) binds CYP3A4 (Gene)
Ivacaftor (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Ivacaftor (Compound) causes Pleuritic pain (Side Effect)
Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Modafinil
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Ivacaftor may lead to a major life threatening interaction when taken with Fluconazole
Ivacaftor may lead to a major life threatening interaction when taken with Crizotinib